Carisma Therapeutics (CARM) Insider Trading & Ownership $0.25 -0.02 (-8.03%) As of 02:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock There is no recent insider trading on record for Carisma Therapeutics, but the stock has been recently traded by U.S. Congress members, who may have more information about the industry than the general public. Get CARM Insider Trade Alerts Want to know when executives and insiders are buying or selling Carisma Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Carisma Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellAverage Share PriceTotal Transaction8/26/2025Ro KhannaU.S. Congress Member (D-CA)Sell$0.24$1,001 - $15,000 (Data available from 1/1/2013 forward) CARM Insider Trading Activity - Frequently Asked Questions What percentage of Carisma Therapeutics stock is owned by insiders? 6.90% of Carisma Therapeutics stock is owned by insiders. Learn more on CARM's insider holdings. Which members of congress are trading Carisma Therapeutics? Ro Khanna (D-CA) has sold shares of Carisma Therapeutics in the last year totaling $8,000. Carisma Therapeutics Key ExecutivesMr. Steven Kelly (Age 59)President, CEO & Director Compensation: $786.91kMr. Michael Klichinsky Ph.D. (Age 34)Pharm.D., PharmD, Co-Founder & Chief Scientific Officer Compensation: $525.43kMr. Richard S. Morris CPA (Age 50)CFO, Chief Compliance Officer, Treasurer, Prin. Financial Off. & Prin. Acc. Off. Compensation: $584.85kDr. Saar Gill M.D.Ph.D., Co-Founder & Chairman of Scientific Advisory BoardMr. Eric H. Siegel J.D. (Age 59)MBA, General Counsel & Corporate Secretary Ms. Terry ShieldsSenior Vice President of Human ResourcesMr. Tom Wilton (Age 50)Chief Business Officer Dr. Eugene P. Kennedy F.A.C.S. (Age 55)M.D., Chief Medical Officer Mr. Kenneth LockeSenior Vice President of Technical Operations More Insider Trading Tools from MarketBeat Related Companies Verrica Pharmaceuticals Insider Selling Century Therapeutics Insider Selling Jasper Therapeutics Insider Selling Xilio Therapeutics Insider Selling LAVA Therapeutics Insider Selling Generation Bio Insider Selling Dyadic International Insider Selling Adaptimmune Therapeutics Insider Selling Pluri Insider Selling Rani Therapeutics Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Top Insider Buys and Sells From September: Buy, Sell, or Hold?NuScale, Rocket Lab Face Heavy Insider Selling After Surges3 Small Caps That Insiders Are Buying $100 Million Buyback in Upwork Stock Follows a Strong Quarter Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t This page (NASDAQ:CARM) was last updated on 10/1/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredTilson: “I’m watching HOOD”A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTrump is Fast-Tracking These Three CompaniesThe Trump administration is planning to invest DIRECTLY in a small sector of the stock market… And they just r...InvestorPlace | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CARM Stock Alerts